Funding for this research was provided by:
Engineering and Physical Sciences Research Council (EP/T001046/1)
Innovate UK (104604)
Wellcome Trust (203257/Z/16/Z)
Received: 31 January 2022
Accepted: 25 July 2022
First Online: 9 August 2022
: D.W. is the managing director of Magnetic Shields Limited, the company which designed and constructed the magnetically shielded room described in this work. J.C., P.N., S.P., P.P., J.W., and N.M. are employees of Magnetic Shields Limited. P.F. receives compensation as a scientific advisor to Magnetic Shields Limited. E.B. D.W. and M.J.B. are directors of Cerca Magnetics Limited, a spin-out company whose aim is to commercialise aspects of OPM-MEG technology. Cerca products include magnetically shielded rooms for biomagnetic measurements from Magnetic Shields Limited. E.B., M.J.B., R.B., N.H. and R.H. hold founding equity in Cerca Magnetics Limited and R.B., N.H. and R.H. sit on the scientific advisory board. E.D. and C.M. are employees of Cerca Magnetics Limited. V.S. is the founding director of QuSpin Inc., a commercial entity selling the OPM magnetometers used in this work. J.O. is an employee of QuSpin Inc. R.P. is the Director of Integrated Care at Young Epilepsy, the charity where the magnetically shielded room described in this work was installed. N.H, J.C., D.W., P.G, M.J.B., and R.B. declare that they have a patent pending to the UK Government Intellectual Property Office (Application No. GB2109459.4) regarding the active magnetic shielding systems described in this work. The remaining authors, M.R., J.L., L.J.E., T.M.T., S.M., G.C.O and G.R.B., declare no competing interests.